Archived from the original on 5 June 2021
Introduction Glucagon-like peptide-1 (GLP-1) receptor agonists and sodium-glucose cotransporter-2 (SGLT-2) inhibitors are second to third line antihyperglycaemic drugs commonly prescribed for the treatment of type 2 diabetes.12 Individually, these drugs have been shown to reduce the risk of cardiorenal events and mortality in large cardiovascular outcome trials.3456789 However, the combined effect of these drug classes on these outcomes has not been extensively studied
In fact, a Anti-obesity medications like Wegovy should not be used for short-term weight loss, but rather long-term treatment of obesity, which is a chronic disease requiring lifelong intervention, says Dr
beyond these criteria for behavioral intervention, no further standardization of behavioral intervention was applied across study sites
Semaglutide mimics a hormone called GLP-1
Patients looking for a doctor-supervised weight management programme can also learn more about Bay Medical's comprehensive semaglutide treatment, where suitability is assessed as part of an individualised medical weight management plan